Expertise
Gastrointestinal oncologyEducation
University of Chicago Pritzker School of MedicineHighlights
Associate professor at Duke University
Expertise in precision cancer medicine
Experienced clinical investigator
I view digital health information as an important tool to help patients find the best available therapies and give them the best possible outcomes. Arming our patients with accurate information helps them form a successful partnership with their doctors.
— John Strickler, MD
Experience
John Strickler, MD, joined the Duke University faculty in 2011 and is now an associate professor of medicine in the division of medical oncology. His research focuses on precision cancer medicine: identification of genomic biomarkers that predict sensitivity or resistance to targeted therapies and immunotherapy.
He has a particular interest in noninvasive “liquid biopsies” to deliver on the promise of precision cancer medicine. He has designed and executed clinical trials that test novel therapies and innovative therapeutic strategies, including first-in-human clinical trials, paradigm-shifting clinical discoveries, and an investigator-sponsored trial that led to a first-in-class FDA-approved anti-HER2 therapy.
As leader of the Duke Cancer Institute Molecular Tumor Board, he leads precision cancer medicine efforts. In addition, he is the associate director for clinical research — GI oncology — at Duke University. He has served as principal investigator for over 50 clinical trials. Nationally, he is a member of the American Society of Clinical Oncology Treatment Guidelines Committee for Advanced Colon Cancer.
Education
John Strickler, MD, is an associate professor at Duke University. He received his B.A. from the University of North Carolina at Chapel Hill and his MD from the University of Chicago Pritzker School of Medicine. He completed his residency in internal medicine at the University of Washington and fellowship in hematology and medical oncology at Duke University.
